sulforaphane has been researched along with Diabetic Nephropathies in 9 studies
sulforaphane: from Cardaria draba L.
sulforaphane : An isothiocyanate having a 4-(methylsulfinyl)butyl group attached to the nitrogen.
Diabetic Nephropathies: KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Diabetic nephropathy is the leading cause of chronic kidney disease and end-stage renal disease." | 2.49 | NF-E2-related factor 2 and its role in diabetic nephropathy. ( Dadras, F; Khoshjou, F, 2013) |
| "Sulforaphane (SFN) prevents diabetic nephropathy (DN) in type 2 diabetes (T2D) by up-regulating nuclear factor (erythroid-derived 2)-like 2 (Nrf2)." | 1.56 | Sulforaphane prevents type 2 diabetes-induced nephropathy via AMPK-mediated activation of lipid metabolic pathways and Nrf2 antioxidative function. ( Cai, L; Guo, H; Li, J; Li, Z; Ma, T; Miao, L; Zhang, Z; Zhou, S, 2020) |
| "Sulforaphane (SFN) prevents diabetic nephropathy (DN) in type 1 diabetes via up-regulation of nuclear factor (erythroid-derived 2)-like 2 (Nrf2)." | 1.42 | Metallothionein plays a prominent role in the prevention of diabetic nephropathy by sulforaphane via up-regulation of Nrf2. ( Cai, L; Chen, X; Cheng, Y; Kong, L; Luo, M; Miao, L; Tan, Y; Wang, Y; Wu, H; Zhang, Z, 2015) |
| "Sulforaphane (SFN) is a compound which is found in cruciferous vegetables and that acts as both a potent antioxidant and regulator of gene expression." | 1.38 | Metabolic effects of sulforaphane oral treatment in streptozotocin-diabetic rats. ( de Assis, AM; de Souza, CG; Perry, ML; Rech, A; Sattler, JA; Souza, DO, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (88.89) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Li, Z | 1 |
| Guo, H | 1 |
| Li, J | 1 |
| Ma, T | 1 |
| Zhou, S | 1 |
| Zhang, Z | 2 |
| Miao, L | 3 |
| Cai, L | 3 |
| Cui, W | 2 |
| Min, X | 1 |
| Xu, X | 1 |
| Du, B | 1 |
| Luo, P | 2 |
| Dadras, F | 1 |
| Khoshjou, F | 1 |
| Shang, G | 1 |
| Tang, X | 1 |
| Gao, P | 1 |
| Guo, F | 1 |
| Liu, H | 1 |
| Zhao, Z | 1 |
| Chen, Q | 2 |
| Jiang, T | 1 |
| Zhang, N | 1 |
| Li, H | 1 |
| Wu, H | 1 |
| Kong, L | 1 |
| Cheng, Y | 1 |
| Wang, Y | 1 |
| Luo, M | 1 |
| Tan, Y | 2 |
| Chen, X | 1 |
| de Haan, JB | 1 |
| Zheng, H | 1 |
| Whitman, SA | 1 |
| Wu, W | 1 |
| Wondrak, GT | 1 |
| Wong, PK | 1 |
| Fang, D | 1 |
| Zhang, DD | 1 |
| de Souza, CG | 1 |
| Sattler, JA | 1 |
| de Assis, AM | 1 |
| Rech, A | 1 |
| Perry, ML | 1 |
| Souza, DO | 1 |
| Bai, Y | 1 |
| Miao, X | 1 |
| Rane, MJ | 1 |
2 reviews available for sulforaphane and Diabetic Nephropathies
| Article | Year |
|---|---|
Role of Nuclear Factor Erythroid 2-Related Factor 2 in Diabetic Nephropathy.
Topics: Animals; Anticarcinogenic Agents; Antioxidant Response Elements; Antioxidants; Curcumin; Cysteine Pr | 2017 |
NF-E2-related factor 2 and its role in diabetic nephropathy.
Topics: Adaptor Proteins, Signal Transducing; Angiotensin-Converting Enzyme Inhibitors; Animals; Anticarcino | 2013 |
7 other studies available for sulforaphane and Diabetic Nephropathies
| Article | Year |
|---|---|
Sulforaphane prevents type 2 diabetes-induced nephropathy via AMPK-mediated activation of lipid metabolic pathways and Nrf2 antioxidative function.
Topics: AMP-Activated Protein Kinases; Animals; Antioxidants; Diabetes Mellitus, Type 2; Diabetic Nephropath | 2020 |
Sulforaphane attenuation of experimental diabetic nephropathy involves GSK-3 beta/Fyn/Nrf2 signaling pathway.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Antioxidants; Cells, Cultured; Collagen Type IV; Deoxyguanosin | 2015 |
Metallothionein plays a prominent role in the prevention of diabetic nephropathy by sulforaphane via up-regulation of Nrf2.
Topics: Animals; Anticarcinogenic Agents; Blotting, Western; Diabetes Mellitus, Experimental; Diabetes Melli | 2015 |
Nrf2 activators as attractive therapeutics for diabetic nephropathy.
Topics: Acrolein; Animals; Diabetic Nephropathies; Humans; Isothiocyanates; NF-E2-Related Factor 2; Sulfoxid | 2011 |
Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy.
Topics: Acrolein; Animals; Cell Proliferation; Cells, Cultured; Cyclin-Dependent Kinase Inhibitor p21; Diabe | 2011 |
Metabolic effects of sulforaphane oral treatment in streptozotocin-diabetic rats.
Topics: Animals; Antioxidants; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Dietary Supplements; Gluco | 2012 |
Prevention of diabetic nephropathy by sulforaphane: possible role of Nrf2 upregulation and activation.
Topics: Animals; Anticarcinogenic Agents; Catalase; Cell Line; Diabetes Mellitus, Experimental; Diabetic Nep | 2012 |